Novel CRISPR-Cas9-Based Promising in ATTR Cardiomyopathy

(MedPage Today) -- CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to phase I data.
A single...